Home Multimedia Podcasts STEM CELL THERAPIES ON THE RISE STEM CELL THERAPIES ON THE RISE February 5, 2009 – Linda Powers, Cofounder and Managing Director of Toucan Capital, is interviewed by GEN’s Editor in Chief, John Sterling /wp-content/uploads/2018/09/gc249_2_5_2009.mp3 Cell therapyClinical trialDrug research and developmentEmbryonic stem cellsGenetic engineeringGenetic Engineering and BiotechnologyMedicineMedicine, Diagnosis, and TherapeuticsPharmacologyPluripotent stem cellsRegenerative engineeringResearch and developmentResearch resourcesStem cell engineeringStem cellsTherapeuticsTranslational medicine Also of Interest T-Cell Therapy in Solid Tumors May Be Improved by Enzyme Syngene Expects Its New Biologics Manufacturing Facility in India to Be Operational from Mid-Year Gastruloids Model Molecular and Cellular Patterns of Early Mammalian Development StockWatch: Blockbuster Sales Projected for Madrigal MASH Drug Machine Learning Can Spot Tumor-Reactive TCRs, Speed Immunotherapies NanoString Finds a Buyer, Slide Tags Enter in Early Access as Curio Trekker, Cellares Unveils Cell Therapy Manufacturing Platform Related Media Sickle Cell Salvation: The Victoria Gray Interview Excitement in Oakland: A Report from SynBioBeta Carl Icahn States His Case for Change at Illumina on "Close to the Edge" Celebrating DNA: Matthew Cobb's Reflections on the Double Helix Emerging Markets Collaborate to Succeed in Post-Pandemic World Book Review: The Exceptions Related Content T-Cell Therapy in Solid Tumors May Be Improved by Enzyme Syngene Expects Its New Biologics Manufacturing Facility in India to Be Operational from Mid-Year Gastruloids Model Molecular and Cellular Patterns of Early Mammalian Development StockWatch: Blockbuster Sales Projected for Madrigal MASH Drug